Literature DB >> 26628841

Animal Models Correlating Immune Cells for the Development of NAFLD/NASH.

Srikanth Iyer1, Pramod Kumar Upadhyay1, Subeer S Majumdar1, Perumal Nagarajan1.   

Abstract

This review mainly elaborates on the animal models available for understanding the pathogenesis of the second hit of non-alcoholic fatty liver disease (NAFLD) involving immune system. This is known to be a step forward from simple steatosis caused during the first hit, which leads to the stage of inflammation followed by more serious liver conditions like non-alcoholic steatohepatitis (NASH) and cirrhosis. Immune-deficient animal models serve as an important tool for understanding the role of a specific cell type or a cytokine in the progression of NAFLD. These animal models can be used in combination with the already available animal models of NAFLD, including dietary models, as well as genetically modified mouse models. Advancements in molecular biological techniques enabled researchers to produce several new animal models for the study of NAFLD, including knockin, generalized knockout, and tissue-specific knockout mice. Development of NASH/NAFLD in various animal models having compromised immune system is discussed in this review.

Entities:  

Keywords:  APPs, acute-phase proteins; BAFF, B cell activating factor; Btk, Bruton's tyrosine kinase gene; DAMPs, damage-associated molecular patterns; HCC, hepatocellular carcinoma; IRFs, Interferon regulatory factors; JNK, c-Jun N-terminal kinase; MCD, methionine choline-deficient; NAFLD; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NLRs, Nod-like receptors; PAMPs, pathogen-associated molecular patterns; immune cells; mouse models

Year:  2015        PMID: 26628841      PMCID: PMC4632099          DOI: 10.1016/j.jceh.2015.06.004

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  66 in total

1.  Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice.

Authors:  Andrew M Miller; Hua Wang; Adeline Bertola; Ogyi Park; Norio Horiguchi; Sung Hwan Ki; Shi Yin; Fouad Lafdil; Bin Gao
Journal:  Hepatology       Date:  2011-09-02       Impact factor: 17.425

2.  Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease.

Authors:  Zhiping Li; Mark J Soloski; Anna Mae Diehl
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

3.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 4.  To be or not to be NKT: natural killer T cells in the liver.

Authors:  Mark A Exley; Margaret James Koziel
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

5.  Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice.

Authors:  Xin-An Wang; Ran Zhang; Dingsheng Jiang; Wei Deng; Shumin Zhang; Shan Deng; Jinfeng Zhong; Tao Wang; Li-Hua Zhu; Li Yang; Shufen Hong; Sen Guo; Ke Chen; Xiao-Fei Zhang; Zhigang She; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Hongliang Li
Journal:  Hepatology       Date:  2013-06-25       Impact factor: 17.425

6.  CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.

Authors:  Satoshi Nishimura; Ichiro Manabe; Mika Nagasaki; Koji Eto; Hiroshi Yamashita; Mitsuru Ohsugi; Makoto Otsu; Kazuo Hara; Kohjiro Ueki; Seiryo Sugiura; Kotaro Yoshimura; Takashi Kadowaki; Ryozo Nagai
Journal:  Nat Med       Date:  2009-07-26       Impact factor: 53.440

7.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

8.  Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Gilles Willemin; Catherine Roger; Armelle Bauduret; Kaori Minehira
Journal:  Int J Endocrinol       Date:  2013-04-24       Impact factor: 3.257

9.  Role of NKT Cells in the Pathogenesis of NAFLD.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2012-04-05

Review 10.  Immune and inflammatory pathways in NASH.

Authors:  Michal Ganz; Gyongyi Szabo
Journal:  Hepatol Int       Date:  2013-08-30       Impact factor: 6.047

View more
  5 in total

1.  Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.

Authors:  Qiang Meng; Xing-Ping Duan; Chang-Yuan Wang; Zhi-Hao Liu; Peng-Yuan Sun; Xiao-Kui Huo; Hui-Jun Sun; Jin-Yong Peng; Ke-Xin Liu
Journal:  Acta Pharmacol Sin       Date:  2016-10-24       Impact factor: 6.150

Review 2.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

3.  Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.

Authors:  Ajay Duseja; Radha K Dhiman; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2020-07-24

4.  A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.

Authors:  Robin D Tucker; Victor Ciofoaia; Sandeep Nadella; Martha D Gay; Hong Cao; Matthew Huber; Anita Safronenka; Narayan Shivapurkar; Bhaskar Kallakury; Annie J Kruger; Alexander H K Kroemer; Jill P Smith
Journal:  Dig Dis Sci       Date:  2019-07-11       Impact factor: 3.199

5.  Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD.

Authors:  Charles I V Drummer; Fatma Saaoud; Yu Sun; Diana Atar; Keman Xu; Yifan Lu; Ying Shao; Candice Johnson; Lu Liu; Huimin Shen; Nirag C Jhala; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  J Immunol Res       Date:  2021-11-23       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.